Specific interactions between DNA and transcription factors are necessary for transcription initiation. These interactions provide a potential target for the selective inhibition of eukaryotic gene expression. Mithramycin is a DNA binding antibiotic which, in the presence of Mg2", binds G-C containing sequences in the minor groove. The SV40 early promoter contains six G-C decanucleotide sequences, which are binding sites for the transcriptional activating factor, Spl. Each of the six Spl binding sites of this promoter is protected from DNAse 1 digestion by mithramycin binding. Mithramycin binding to the G-C rich sequences in the SV40 early promoter prevents subsequent protein binding to these sequences. The gel retardation of the SV40 early promoter fragment incubated with a HeLa cell extract is completely abrogated by pretreatment of the DNA fragment with mithramycin. The functional significance of mithramycin binding is reflected in the ability of mithramycin to block promoter function. Mithramycin inhibits promoter dependent transcription in an in vitro runoff transcription system in a concentration dependent manner. This suggests that mithramycin prevents transcriptional activation of the SV40 early promoter by blocking binding of transcriptional activating proteins to G-C rich promoter regions.
Introduction
Gene expression in higher eukaryotic cells is mediated by systematic control of RNA synthesis. Formation of the transcription initiation complex involves interaction of a number of cellular factors which bind specific DNA sequences located within the promoter regions of eukaryotic genes (1) (2) (3) (4) . It is likely that both temporal and tissue specific gene expression are controlled, at least in part, by the interaction of these factors with DNA.
The most well characterized transcription factor is Spl (5) which was first detected in HeLa cells on the basis of its ability to activate the SV40 early promoter. Tjian and his co-workers have shown that SpI recognizes and binds selectively to a GC rich decanucleotide sequence (6, 7) . This "G-C box" sequence is present as six tandem copies in SV40 early promoter. Spl interacts with the GC box sequences by forming protein-DNA complexes in the major groove of DNA. Sp I binding appears to be necessary for transcriptional activation ofthe SV40 early promoter (6) (7) (8) (9) (10) (11) (12) .
Spl can also activate transcription of other viral and cellular genes which have one or more GC box elements in their 5' flanking promoter sequences. Genes whose promoters contain such sequences include the HSV-TK (herpes simplex virusthymidine kinase) (13) , human metallothionein IIA (14) , dihydrofolate reductase (15) , and the Ha-ras protooncogene (16) . The human c-myc gene also has short G-C rich sequences 5' of both the PI and P2 promoters, but does not contain consensus Spl binding sites. The importance of these sequences in the regulation of cellular gene expression is not known.
Mithramycin is a G-C specific DNA binding antibiotic that inhibits RNA synthesis initiation (17, 18) . It inhibits binding of Escherichia coli RNA polymerase to a poly dGo dC template, but does not inhibit binding to a poly dA * dT template (18) . This suggests that mithramycin may bind to G-C-rich sequences in eukaryotic promoters and inhibit RNA synthesis by preventing binding of regulatory proteins, such as Spl, to these sites.
Mithramycin is an effective differentiating agent of HL60 promyelocytic leukemia cells, as well as the leukemic cells of certain patients with the myeloid blast phase of chronic myelogenous leukemia (19, 20) . Treatment ofleukemic cells with this agent is accompanied by an early dramatic decrease in c-myc expression, which precedes differentiation by 24-48 h. Expression of the c-myc protooncogene is selectively inhibited by mithramycin treatment in a number of differentiating and nondifferentiating cell types (21) .
We have used the SV40 early promoter sequence to correlate the specificity and effects of mithramycin binding. 30 'C. The reaction was terminated by the addition of 100 Ml of termination buffer (1% sarkosyl, 100 mM NaCl, 100 mM Tris-HCl, pH 8.0 100 mM EDTA) and extracted twice with phenol followed by chloroform, and ethanol precipitation. The reaction mix was analyzed by electrophoresis on a 6% polyacrylamide-urea gel.
Results
The mithramycin binding sites on the SV40 early promoter were determined by DNAse I protection assays. Fig. 1 shows the binding of mithramycin to the SV40 promoter region as detected by the DNAse I protection. An 89-bp fragment ofthe SV40 promoter region ( Fig. 1 A) , which contains the six "G-C box" recognition sites for Spl, was incubated with varying concentrations of mithramycin before DNAse I digestion. As shown in Fig. 1 B, mithramycin binds selectively to the G-C box regions ofthe SV40 promoter, in a fashion nearly identical to binding of Spl (10) . It also binds to shorter G-C containing sequences in this DNA fragment, although to a lesser degree. The footprinting pattern is mithramycin concentration dependent (data not shown) and maximal binding occurs at DNA/mithramycin ratios that result in RNA synthesis inhibi- (Fig. 1 A) containing six G-C boxes was used for DNAse 1 footprinting reactions. The footprint result (B) shows that most of the G and C residues were protected by mithramycin. The sequence of protected G-C region corresponds to the "G-C" box regions of the early promoter of SV40. tion. Mithramycin appears to require at least three consecutive G or C residues for effective binding. This is consistant with the previous observations regarding mithramycin binding to the lac operon (27) .
Binding of the partially purified recombinant Spl product of the Spl-5 16c plasmid and mithramycin were compared as shown in Fig. 2 . The binding patterns of mithramycin and the recombinant Spl to the G-C-rich portion of the SV40 early promoter were similar, but not identical. Mithramycin appears to recognize all of the sequences bound by Spl, but also binds to additional G-C-rich sequences. This most likely reflects the smaller size of the drug compared to the recombinant Spl .
Gel retardation studies were used to determine whether the binding of mithramycin to the G-C box regions of the SV40 early promoter region may prevent sequence-specific protein binding. The effect of mithramycin binding on the specific changes in gel mobility of the SV40 early promoter fragment, induced by a partially purified HeLa cell extract, enriched in Spl were examined. As shown in Fig. 3 to the SV40 promoter, we also measured the effect of mithramycin on the cell-free runoff transcription of this sequence by a whole cell HeLa cell extract (29). We determined the ability of the whole cell extract to transcribe the PLl plasmid linearized with Eco RI (22). This plasmid contains both the SV40 early and late promoter region (shown in Fig. 5 A) but RNA polymerase II transcribes only from the early promoter. As shown in Fig. 5 Fig. 3 B.
The gel mobility shift analysis of recombinant Sp1 (Sp 1-5 1 6c) binding to the SV40 early promoter in the presence or absence of mithramycin is shown in Fig. 4 . This experiment demonstrates that recombinant Spl is unable to bind to the SV40 early promoter when the DNA has been preincubated with mithramycin (lane 2). However, in the absence of the promoter-dependent transcription. Addition of mithramycin to the reaction mixture results in concentration-dependent inhibition of promoter-specific transcription. (30) . It is likely that both chromatin structure and sequence specificity determine the cellular effect of DNA binding drugs.
The G-C specificity of DNA binding by mithramycin suggests that expression of genes regulated by G-C binding proteins may be selectively sensitive to this agent. This is supported by the observation that expression of the c-myc, c-Haras, and c-abl genes is selectively inhibited by mithramycin (21) . These genes have G-C-rich promoter regions and the c-Ha-ras gene contains consensus Sp 1 binding sites. The binding specificity of mithramycin for G-C residues may allow the selective inhibition of expression of a group of genes with G-C-rich promoters. Although the number of eukaryotic genes whose promoter regions contain G-C box sequences (or closely related sequences) is not known, a number ofSpl binding sites of varying affinity have been identified (31) . Mithramycin may inhibit expression of all of these genes to a varying degree. 5 The cellular effects of mithramycin may be dictated by its selective inhibition of expression of genes with G-C-rich promoters. Mithramycin induces myeloid differentiation of leukemic cells in certain patients with chronic granulocytic leukemia (18, 19) which is accompanied by an early decrease in c-myc expression. The differentiation of leukemic cells in which c-myc expression is specifically inhibited by the presence of antisense DNA sequences (32, 33) suggests that decreased c-myc expression alone may be adequate to induce differentiation of these cells. Our data suggest that mithramycin may selectively block formation of the transcription initiation complex of genes with G-C-rich promoter regions, including the c-myc gene.
